Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Clinical Oncology (ASCO)
American Society of Clinical Oncology (ASCO)
The
American Society of Clinical Oncology
(
ASCO
) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.
A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study
ASCO 2016 – Lung Cancer
Read More ›
A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13
ASCO 2016 – Lung Cancer
Read More ›
Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study
ASCO 2016 – Lung Cancer
Read More ›
An open-label phase 2 trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928)
ASCO 2016 – Lung Cancer
Read More ›
Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN solid tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression
ASCO 2016 – Lung Cancer
Read More ›
Bayesian randomized trial comparing intensity-modulated radiation therapy versus passively scattered proton therapy for locally advanced non–small-cell lung cancer
ASCO 2016 – Lung Cancer
Read More ›
Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression
ASCO 2016 – Lung Cancer
Read More ›
E1505: Adjuvant chemotherapy ± bevacizumab for early stage NSCLC—outcomes based on chemotherapy subsets
ASCO 2016 – Lung Cancer
Read More ›
Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC)
ASCO 2016 – Lung Cancer
Read More ›
Videos
Utilizing Chemotherapy to Treat Lung Cancer
ASCO 2016 – Lung Cancer
Benjamin P. Levy, MD, talks about the role chemotherapy currently plays in an arena where the cancer care team is emphasizing genomic profiling and targeted therapies to treat patients with lung cancer.
Read More ›
Page 18 of 29
15
16
17
18
19
20
21
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us